Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis
| Status: | Recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | June 2011 |
| End Date: | June 2017 |
| Contact: | UC Cancer Institute |
| Phone: | 513-584-7698 |
A Phase II Trial to Evaluate the Use of Trental and Vitamin E for Prophylaxis of Radiation Necrosis
The purpose of this study is to determine whether the use of Trental and Vitamin E can help
reduce the incidence of radiation necrosis (a lesion that usually occurs at the original
tumor site) after radiosurgery. These two drugs are commonly used to treat radiation
necrosis when it occurs but the hope is that these drugs can be used to prevent radiation
necrosis from ever occurring.
reduce the incidence of radiation necrosis (a lesion that usually occurs at the original
tumor site) after radiosurgery. These two drugs are commonly used to treat radiation
necrosis when it occurs but the hope is that these drugs can be used to prevent radiation
necrosis from ever occurring.
The treatment phase of the study is 6 months. Study procedures will be conducted such as:
history, physical and neurological exam, pregnancy testing (for women of child bearing age)
and a Brain MRI. Follow-up appointments will be every 3 months for 1 year at which time,
your participation in the study will be concluded.
history, physical and neurological exam, pregnancy testing (for women of child bearing age)
and a Brain MRI. Follow-up appointments will be every 3 months for 1 year at which time,
your participation in the study will be concluded.
Inclusion Criteria:
- Plan to undergo single or five fraction radiosurgery for a metastatic brain tumor
- Diagnosis of a metastatic brain tumor may be accomplished by histologic confirmation
or by clinical confirmation by the treating physician based on MR imaging
characteristics in the setting of a known history of cancer
- Age > 18 years
- Partial or total resection of a metastatic tumor are eligible
Exclusion Criteria:
- Known sensitivity to vitamin E or Trental
- Recent intracranial bleed or retinal hemorrhage
- Treatment with a non-approved or investigational drug within 30 days before day 1 of
study treatment
- History of Avastin treatment
- Anticipated need for treatment with Avastin
- History of bleeding disorder
- History of liver disorder
We found this trial at
1
site
2600 Clifton Ave
Cincinnati, Ohio 45267
Cincinnati, Ohio 45267
(513) 556-6000
Principal Investigator: Ronald Warnick, MD
Phone: 513-584-7698
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
Click here to add this to my saved trials
